Tyrosine Kinase Inhibitor-induced cardiotoxicity in hiPSC derived cardiomyocytes - pilot dataset

To define molecular network markers of tyrosine kinase inhibitor-induced cardiotoxicity, we treated human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) with one of four tyrosine kinase inhibitors displaying a range of mild to severe effects on heart function (Erlotinib, Lapatinib, Sorafenib, or Sunitinib) or vehicle control (DMSO). We performed 6 different treatments for each drug, including three doses (1, 3.16 and 10 µM) at 24 hours and the intermediate dose (3.16 µM) for an additional three time points (6h, 72h and 168h). Gene expression changes were assessed at the cell population level using total RNA-Seq, which measured levels of both mRNAs and long non-coding RNAs. Validation of RNA-Seq results was performed by qPCR (HMS-LINCS Dataset #20325).